the Voting Panel considered Patient Panel input and recognized that there may be patients who would prefer (or benefit from) ULT, underscoring the need for shared decision-making. As noted above, data from the RCT of patients with â‰¤2 previous flares (and no more than 1 gout flare in the preceding year) supported the benefit of ULT for reduction of SU concentration and gout flare risk Certainty of evidence For patients with 1 or more subcutaneous tophi, we strongly recommend initiating ULT over